Japan Intravenous Iron Drugs Market Size, Share, and COVID-19 Impact Analysis, By Drug Type (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, and Other Drug Types), By Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, and Other Applications), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Japan Intravenous Iron Drugs Market Insights, Industry Trend, Forecasts to 2035

Japan Intravenous Iron Drugs Market Size Insights Forecasts to 2035

• The Japan Intravenous Iron Drugs Market Size Was Estimated at USD 62.7 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 21.13% from 2025 to 2035
• The Japan Intravenous Iron Drugs Market Size is Expected to Reach USD 516.4 Million by 2035

According to a research report published by Spherical Insights & Consulting, the Japan intravenous iron drugs market Size is anticipated to reach USD 516.4 million by 2035, growing at a CAGR of 21.13% from 2025 to 2035. The Japan intravenous iron drugs market is expanding due to increasing cases of chronic kidney disease and cancer, an aging society, and better formulations of drugs. The transition towards outpatient services and the need for immediate iron replenishment also promote growth in the market.

Market Overview

The Japan intravenous iron drugs market refers to drugs taken by injection to correct iron deficiency anemia in patients with chronic kidney disease, cancer, or gastrointestinal disorders, where oral iron is not effective or is poorly tolerated, for faster and effective iron supplementation. Key strengths are a strong domestic pharmaceutical sector, strict PMDA regulation guaranteeing quality products, and fast elevate of sophisticated IV preparations. Opportunities include growth in oncological anemia, pediatrics indications, and the emergence of new formulations such as ferric derisomaltose (MonoVer), which has been recently introduced with national insurance coverage. Drivers are Japan aging population, increasing incidence of chronic diseases, and better understanding of IDA treatment. Government and healthcare stakeholders are driving anemia awareness, increasing reimbursement policies, and facilitating infusion therapy in clinical pathways.

Report Coverage

This research report categorizes the market for the Japan intravenous iron drugs market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan intravenous iron drugs market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan intravenous iron drugs market.

Driving Factors

The Japan intravenous iron pharmaceuticals market is supported by a fast-growing population of elderly people, rising incidence of chronic diseases like chronic kidney disease, inflammatory bowel disease, and cancer-related anemia. Increased awareness of iron deficiency anemia and its effects on quality of life is enhancing demand for effective treatment. Innovations in intravenous products such as ferric carboxymaltose and ferric derisomaltose, combined with favorable government healthcare policy and enhanced reimbursement coverage, are further driving market uptake in hospitals, dialysis clinics, and outpatient facilities.

Restraining Factors

The Japan intravenous iron medications market is under the constraint of expensive treatment, restricted reimbursement in a number of outpatient facilities, high PMDA regulatory procedures, safety issues related to hypersensitivity reactions, and competition from costlier oral iron supplements, which can hinder uptake.

Market Segmentation

The Japan intravenous iron drugs market share is classified into drug type, application, and distribution channel.

• The ferric carboxymaltose segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan intravenous iron drugs market is segmented by drug type into iron dextran, iron sucrose, ferric carboxymaltose, and other drug types. Among these, the ferric carboxymaltose segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to they provide a large elemental iron dose in lower volumes, decreasing infusion frequency and increasing patient convenience. Its rapid administration, usually about 15 minutes, is advantageous for patients who require rapid iron replenishment and enables healthcare professionals to maximize the efficiency of treatment.

• The chronic kidney disease segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan intravenous iron drugs market is segmented by application into chronic kidney disease, inflammatory bowel disease, cancer, and other applications. Among these, the chronic kidney disease segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is attributed to the frequent causes of anemia from low erythropoietin and inflammation. IV iron quickly corrects iron deficiency, increasing hemoglobin and red blood cell production. Faster relief is achieved compared with oral supplements and is also better tolerated, lessening gastrointestinal side effects in CKD patients.

• The hospital pharmacy segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan intravenous iron drugs market is segmented by distribution channel into hospital pharmacy, retail pharmacy, and online pharmacy. Among these, the hospital pharmacy segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to their expertise in handling IV iron treatments, maintaining correct formulation, dosing, and regimens adapted to patients. They watch for side effects, modify treatments according to patient response and laboratory data, reducing the possibility of errors and enhancing safety and efficacy during the therapy.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan intravenous iron drugs market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Daiichi Sankyo Co., Ltd.
• Sanofi S.A.
• Mitsubishi Tanabe Pharma
• Kyowa Kirin Co., Ltd.
• Astellas Pharma Inc.
• Chugai Pharmaceutical Co., Ltd.
• AMAG Pharmaceuticals
• Nippon Shinyaku Co., Ltd.
• AbbVie
• Sumitomo Pharma Co., Ltd.
• Pharmacosmos
• Vifor Pharma
• Others

Recent Developments:

• In March 2023, Pharmacosmos announced that MonoVer® (ferric derisomaltose) has gained national reimbursement in Japan and is launching in the world’s third-largest pharma market. This intravenous iron treats iron deficiency anemia when oral iron is ineffective or rapid delivery is required. Nippon Shinyaku Co., Ltd., Pharmacosmos’ strategic partner with over 2,000 employees and a century of innovation, introduces the product.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan intravenous iron drugs market based on the below-mentioned segments:

Japan Intravenous Iron Drugs Market, By Drug Type

• Iron Dextran
• Iron Sucrose
• Ferric Carboxymaltose
• Other Drug Types

Japan Intravenous Iron Drugs Market, By Application

• Chronic Kidney Disease
• Inflammatory Bowel Disease
• Cancer
• Other Applications

Japan Intravenous Iron Drugs Market, By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy